Evan's Life is Turned Upside Down by Diagnosis of PNH
Evan biked daily. He had no symptoms. The diagnosis was fast, but surprising. Evan shares his remarkable story in this episode.
treatment
Approval of Fabhalta (iptacopan), Oral Medication for Patients with PNH
What does this FDA approval mean for patients with PNH? Find out how this oral medication, Fabhalta, could replace one of the infusion treatments in this interview with Dr. Bart Scott.
FDA approval of Tibsovo with Dr. Amir Fathi
Here is a discussion about recent FDA approval of Tibsovo for Relapsed/Refractory MDS with Dr. Amir Fathi, who is an Associate Professor of Medicine at Harvard Medical School and the Director of the Leukemia Program at Massachusetts General Hospital.
Expanded Access to Reblozyl® for Patients with Dr. Guillermo Garcia Manero
This episode focuses on the US Food and Drug Administration expanded access approval of luspatercept or Reblozyl with Dr. Guillermo Garcia-Manero, Chief of the Section of MDS in the Department of Leukemia at MD Anderson Cancer Center in Houston.
Medical Jargon Made Simple
Caregivers: What to Expect When Your Loved One is Diagnosed
In this webinar, Dr. Thota will discuss what caregivers can expect when their loved one is diagnosed- symptoms and side effects of disease and treatments.
2023 EHA/ASCO Updates: MDS and AML
Dr. Lai discusses the latest research presented at the 2023 EHA and ASCO meetings. This is an advanced educational presentation.
Biosimilars - Treatment Options for Patients
Aplastic Anemia and Non-Transplant Therapies from the 2023 Phoenix Patient-Family Conference
Genetics and MDS
In this webinar, Jennie Vagher, certified genetic counselor, discusses hereditary or genetic predisposition to MDS. Jennie is an expert in rare cancer predisposition syndromes.